Merck KGaA has entered into a definitive agreement to acquire SpringWorks Therapeutics for $47 per share in cash, valuing the deal at approximately $3.9 billion in equity and $3.4 billion in enterprise value. The offer represents a 26% premium to SpringWorks' 20-day volume-weighted average price, with the closing expected in late 2025. This acquisition aims to expand Merck KGaA's U.S. presence and its portfolio in rare cancer treatments, including a drug approved in February. Separately, Kronos Bio has agreed to be acquired by Concentra Biosciences for $0.57 in cash per share plus a contingent value right. This offer has prompted investigations by law firms into whether the sale price is fair to shareholders. Additionally, shareholder alerts and securities fraud investigations have been announced concerning Regulus Therapeutics, Open Lending Corporation, and Eagle Bancorp, highlighting ongoing scrutiny in the biotech and financial sectors.